GTx files toremifene in US for bone fractures
This article was originally published in Scrip
Executive Summary
GTx has submitted a US NDA for its oral selective oestrogen receptor modulator (SERM), toremifene 80mg, for the prevention of bone fractures in men with prostate cancer who are receiving androgen deprivation therapy (ADT).